Genmab shares jumped 8.3% after positive late-stage trial results for Epkinly in diffuse large B-cell lymphoma. The drug, developed with AbbVie, reduced risk of disease progression or death by 51% when added to standard treatment. Analysts say results exceeded expectations and could change front-line treatment.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
